On April 22, 2026, the federal government took its most consequential step in drug policy reform in over half a century when it reclassified certain marijuana products to Schedule III from Schedule I.
For decades, the Schedule I designation—which placed marijuana alongside heroin and LSD—asserted that the substance had “no currently accepted medical use” and a high potential for abuse. By moving medical cannabis to Schedule III, the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) have officially acknowledged that marijuana possesses a “moderate to low potential for physical and psychological dependence,” placing it in the same legal category as substances like ketamine, anabolic steroids, and acetaminophen with codeine (Ogletree Deakins, 2026).
A Two-Tiered Framework
The order does not constitute “legalization” in the sense that many activists desire. As noted by legal analysts at Saul Ewing, the DOJ has created a distinct two-tier federal framework. FDA-approved marijuana products and cannabis authorized under valid state medical licenses are now Schedule III, but “unlicensed adult-use marijuana, bulk marijuana not yet incorporated into an approved product, and synthetic THC” remain strictly controlled as Schedule I substances (Saul Ewing, 2026).
This distinction highlights that the federal government is prioritizing a medical and administrative path forward rather than endorsing a broad, recreational market. For medical operators, however, the reclassification is a momentous victory. As McCarter & English points out, the shift may finally lead to the erosion of Section 280E of the Internal Revenue Code, which has long prevented cannabis businesses from taking ordinary tax deductions, effectively crippling their profitability and keeping many in the red (McCarter & English, 2026).
The Road to June 29
While this order is effective immediately, the DOJ has simultaneously initiated an expedited administrative hearing process. This hearing, scheduled to begin on June 29, 2026, will evaluate the broader implications of rescheduling the totality of marijuana. As the Department of Justice press release explains, this new hearing is designed to provide a “timely and legally compliant pathway” to evaluate not just the limited medical products currently addressed, but the potential status of the wider industry under federal law (U.S. Department of Justice, 2026).
Legal observers suggest this move is an effort to harmonize U.S. domestic policy with international obligations under the Single Convention on Narcotic Drugs. By dragging the administration of cannabis policy into a more rational schedule, the government is attempting to modernize a regulatory structure that had become hopelessly disconnected from the social reality of the last twenty years (Holland & Knight, 2026).
Implications for the Workforce and Beyond
The transition to Schedule III is already rippling through the private sector. Employers, particularly those in regulated sectors like transportation, are now forced to grapple with the tension between federal status and state licensure. While the Department of Transportation (DOT) has maintained for now that its drug testing prohibitions remain in place, legal experts warn that the shift to Schedule III will likely invite more litigation under the Americans with Disabilities Act (ADA). Employees may increasingly challenge adverse actions based on medicinal marijuana use, citing the federal recognition of the drug’s therapeutic value as a basis for accommodation requests (Ogletree Deakins, 2026).
Ultimately, this administrative policy change reflects a pragmatic recognition of state-level realities. The current administration has opted for a controlled integration of medical cannabis into the existing federal administrative apparatus. While the ultimate fate of recreational-use cannabis remains a matter for the upcoming June hearings and potential future congressional action, the era of absolute federal prohibition against medical marijuana is effectively over. We are now entering a phase where the nuances of federal administrative registration, tax code compliance, and institutional policy will determine the future of the industry. The outcome of the June 29 hearing will be the next major indicator of whether this “medical lens” approach will eventually widen to include the broader market or remain a targeted shift for patients and practitioners alone.
The reclassification is expected to impact obligations to accommodate employees with disabilities under the ADA. Employers are still able to prohibit employees from working under the influence, especially in safety-sensitive positions. While the reclassification does not prohibit employers from testing employees for THC, such tests are now considered “medical examinations” under the ADA that may only be conducted when job-related and consistent with business necessity. Employers should use this reclassification as an opportunity to proactively review their drug testing policies.
References
Holland & Knight (2026). “Cannabis Rescheduling: DOJ Announces Formal Process.” Holland & Knight Insights.
McCarter & English (2026). “DOJ Reclassifies Medical Marijuana to Schedule III.” McCarter & English Legal Insights.
Ogletree Deakins (2026). “DOJ Orders Immediate Reclassification of Medical Marijuana Products.” Ogletree Deakins Employment Law Blog.
Saul Ewing (2026). “DEA Reschedules FDA-Approved Marijuana Products and State-Licensed Medical Marijuana.” Saul Ewing Legal Alert.
U.S. Department of Justice (2026). “Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana in Schedule III.” justice.gov.
James P. Randisi, President of Randisi & Associates, Inc., has been helping employers protect their clients, workforce and reputation through implementation of employment screening and drug testing programs since 1999. This post does not constitute legal advice. Randisi & Associates, Inc. is not a law firm. Always contact competent employment legal counsel. To learn more about the rights of employees who test positive for marijuana, Mr. Randisi can be contacted by phone at 410.336.0287 or Email: info@randisiandassociates.com or the website at Randisiandassociates.com
